Aeon Global Health Announces Exclusive Marketing and Sales Agreement for Trusted Branded Pharmaceutical
- Tuesday, January 23, 2018
- GAINESVILLE, Ga
Company to market non-opiate pain management drug along with its drug monitoring services to physicians and healthcare facilities on nationwide basis
Gainesville, GA, January 23, 2018: Aeon Global Health, the operating arm of Authentidate Holding Corp (ADAT: OTCQB), a growth-oriented provider of personalized, clinically actionable medical informatics and telemedicine, announced today that it has agreed with Sabal Therapeutics, LLC to be the primary laboratory marketer of Naprosyn®, the branded naproxen oral suspension USP. Under the agreement, Aeon will become the exclusive clinical laboratory marketing representative of Sabal and will market the drug alongside of its industry-leading drug monitoring service, thus providing physicians with an integrated, non-opiate solution for pain management.
In a recent study of 5,500 patients, it was concluded that both NSAIDs and opioids provided the same level of acute pain relief. “With the declaration in October 2017 by President Trump that the opioid epidemic is a nationwide public health emergency, we believe that the combination of providing an alternative to these drugs with our state-of –the art drug monitoring services will be a welcome alternative for pain management, said Sonny Roshan, Chairman and Chief Executive Officer of Aeon Global Health. Moreover, we believe that combining our testing with this unique pain medication alternative can result in both improved patient outcomes and a reduction in adverse drug reactions so common with some of the opioids. Aeon is committed to offering unsurpassed levels of patient care in a manner that is cost effective, and we believe this agreement with Sabal Therapeutics can achieve both of these core Company goals.”
Because Naprosyn® is dispensed in a liquid form, healthcare professionals can more accurately prescribe and adjust the dosage based on individual patient needs, especially for patients whose weight, medical condition or pain severity appropriately warrant flexible dosing versus the fixed dosage of tablets. In addition, because Naprosyn® is dispensed in a liquid form rather than in a tablet, the difficulty that a number of people, especially those over 50 years of age, may have with swallowing pills is reduced.
ABOUT AUTHENTIDATE/AEON GLOBAL HEALTH
Authentidate Holding Corp. (OTCQB: ADAT),through its Aeon Global Health operating arm, is an emerging leader provision of clinically actionable medical informatics. Founded in 2010, Aeon is focused on the delivery of services consistent with federal quality standards and which exceed industry standards for turn-around time. Operating out of a modern 30,000 square-foot facility in suburban Atlanta, the Company provides a comprehensive menu of diagnostic and laboratory- developed tests as well as interpretative data for a wide range of inherited conditions.
ABOUT SABAL THERAPEUTICS, LLC
Sabal Therapeutics is a pharmaceutical commercialization services company based in Athens, Georgia. The company employs an innovative business model designed to allow domestic entrepreneurs and international in the pharmaceutical companies to gain a foothold or otherwise participate in the robust US market. In addition to technical services, clients have access to sales, marketing and administrative expertise and, if desired, turn-key entry into the pharma space.
Except for historical information, the matters discussed in this press release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this release, words such as “believe”, anticipate” think”, “intend”, “plan”, “will be”, “expect” or similar expressions identify such forward looking statements. In addition, such statements include declarations regarding the intent, belief or current expectations of Authentidate Holding Corp. and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, for example, the markets for the Company's services, costs of and services, other expenses, government regulations, litigation, and general business conditions. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Other risks and uncertainties are more fully described in our reports filed with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.
Smith S, Deshpande B, Collins J, et. al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee
osteoarthritis: systematic analytic review. Osteoarthritis and Cartilage 24 (2016) 962-972.
Edwards R. Is there a “best” pain reliever for osteoarthritis? https://www.health.harvard.edu/blog/is-there-a-best-pain-reliever-for-osteoarthritis